JP
BMRN icon

Jana Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jana Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-92,030
Closed -$8.08M – 50
2017
Q1 		$8.08M Sell
92,030
-1,893
-2% -$168K 0.15% 38
2016
Q4 		$7.78M Buy
93,923
+41,033
+78% +$3.53M 0.14% 40
2016
Q3 		$4.89M Buy
+52,890
New +$4.98M 0.09% 42

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jana Partners's BMRN Position: Q2 2017 in Review

Jana Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2017, closing a stake of 92,030 shares — an estimated $8.08M sold.

Jana Partners first reported a position in BMRN in Q3 2016 and held it in 3 quarters. The position peaked at $8.08M in Q1 2017. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

  • Jana Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Jana Partners sold 92,030 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $8.08M.
  • Jana Partners first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Jana Partners's BioMarin Pharmaceuticals position peaked at $8.08M in Q1 2017.
  • 426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on Jana Partners's 13F filing for Q2 2017, filed 14 Aug 2017.